Compass Therapeutics' (CMPX) "Buy" Rating Reaffirmed at D. Boral Capital

Compass Therapeutics (NASDAQ:CMPX - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They currently have a $32.00 price target on the stock.

Other equities research analysts have also recently issued reports about the company. Leerink Partnrs cut Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, November 15th. Guggenheim started coverage on Compass Therapeutics in a research note on Monday. They set a "buy" rating and a $12.00 price objective for the company. HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Compass Therapeutics in a report on Wednesday, January 8th. Jefferies Financial Group upped their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a report on Monday, February 10th. Finally, Leerink Partners cut shares of Compass Therapeutics from an "outperform" rating to a "market perform" rating and dropped their price target for the company from $5.00 to $4.00 in a research report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $11.38.

Compass Therapeutics Trading Down 0.7 %

Shares of CMPX traded down $0.02 during mid-day trading on Tuesday, reaching $2.90. The company's stock had a trading volume of 675,954 shares, compared to its average volume of 1,954,389. Compass Therapeutics has a 52 week low of $0.76 and a 52 week high of $4.08. The stock has a market cap of $399.01 million, a PE ratio of -7.84 and a beta of 1.17. The company's fifty day moving average price is $2.56 and its two-hundred day moving average price is $1.93.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Research analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CMPX. Squarepoint Ops LLC purchased a new position in shares of Compass Therapeutics during the fourth quarter valued at about $35,000. Tang Capital Management LLC boosted its position in Compass Therapeutics by 225.4% during the 4th quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock valued at $8,555,000 after acquiring an additional 4,087,005 shares in the last quarter. ProShare Advisors LLC grew its holdings in shares of Compass Therapeutics by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock worth $42,000 after acquiring an additional 9,451 shares during the period. MPM Bioimpact LLC raised its position in shares of Compass Therapeutics by 51.9% in the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock worth $12,423,000 after acquiring an additional 2,926,002 shares in the last quarter. Finally, Enavate Sciences GP LLC bought a new position in shares of Compass Therapeutics in the 4th quarter worth approximately $11,293,000. 68.43% of the stock is currently owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.